AGEN vs AZN

AGEN's deterministic health scores are severely compromised: a Piotroski F-Score of 0/9 signals extreme financial distress, and the absence of an Altman Z-Score with negative profitability and liquidity ratios indicates high bankruptcy risk. Despite a 20.4% YoY revenue growth and recent EPS improvement, the company remains unprofitable with a -32.92% profit margin and negative ROA. The stock trades at a price/sales of 1.35, but with no intrinsic value or Graham Number, it lacks a fundamental floor. Analysts' target price of $12.33 is not supported by current fundamentals, suggesting overvaluation based on speculative growth expectations.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.